Page last updated: 2024-12-05

hesperetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Hesperetin is a flavonoid found in citrus fruits, particularly in the peels and pith. It exhibits various biological activities, including antioxidant, anti-inflammatory, and anticancer properties. Hesperetin has been shown to protect against oxidative stress, reduce inflammation, and inhibit the growth of cancer cells. Its potential health benefits have led to extensive research on its mechanisms of action and its role in human health. Hesperetin is synthesized through a complex biosynthetic pathway in citrus plants, involving enzymes like chalcone synthase and flavanone 3-hydroxylase. It is typically extracted from citrus fruit peels or synthesized in the laboratory. Researchers are studying hesperetin for its potential use in the prevention and treatment of various diseases, such as cardiovascular disease, diabetes, and cancer. Due to its natural occurrence in citrus fruits and its potential therapeutic benefits, hesperetin is considered an important dietary flavonoid.'

Cross-References

ID SourceID
PubMed CID3593
CHEMBL ID88169
CHEBI ID95167
SCHEMBL ID765368
MeSH IDM0060438
PubMed CID72281
CHEMBL ID399121
CHEBI ID28230
SCHEMBL ID39833
MeSH IDM0060438

Synonyms (170)

Synonym
smr001557653
NSC641520 ,
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4h-chromen-4-one
5,7-dihydroxy-2-(3-hydroxy-4-methoxy-phenyl)chroman-4-one
NCI60_014043
nsc-641520
3',7-trihydroxy-4'-methoxyflavanone
5,3'-trihydroxy-4'-methoxyflavanone
nsc57654
flavanone,5,7-trihydroxy-4'-methoxy-
mls002667896 ,
4h-1-benzopyran-4-one,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (s)-
ACON1_002327
NCGC00095618-01
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one
NCGC00095618-02
FE387278-0643-4EBB-902D-C81B1FCDE1F8
BRD-A44482398-001-01-3
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one
AKOS015995360
CHEMBL88169
FT-0626940
4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2s)-
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-chromanone
hesperetine
69097-99-0
HMS3373J01
SCHEMBL765368
mfcd00075646
DTXSID80274404
CHEBI:95167
(+/-)-hesperetin, analytical standard
hesperetin, analytical standard
HMS3656C03
hesperetin, >=95%
Q27166968
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-one
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-chromanone, 3',5,7-trihydroxy-4-methoxyflavanone
(rac)-hesperetin
HY-N0168A
CS-0111125
(+/-)-hesperetin
AS-11672
SY057338
XH167423
rac-hesperetin
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4h-1-benzopyran-4-one
DTXSID70859446
(r)-hesperetin
EN300-23521574
BIDD:ER0512
MLS002154205
smr001233491
BRD-K30553453-001-05-8
DIVK1C_001039
KBIO1_001039
SDCCGMLS-0066605.P001
nsc-57654
cyanidanon 4'-methyl ether 1626
SPECTRUM_000181
SPECTRUM4_001935
PRESTWICK_908 ,
cas-520-33-2
NCGC00016482-01
tnp00238
NCGC00016482-02
PRESTWICK3_000124
BPBIO1_000186
BCBCMAP01_000087
IDI1_001039
BSPBIO_002808
BSPBIO_000168
yso2
4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (s)-
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxy-phenyl)chroman-4-one
hesperitin
3',5,7-trihydroxy-4'-methoxyflavanone
hesperetin ,
C01709
520-33-2
DB01094
OPREA1_828704
SPECTRUM5_000683
(-)-(s)-hesperetin
CHEBI:28230 ,
(-)-hesperetin
NCGC00142415-01
(s)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one
NCGC00142415-02
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4h-chromen-4-one
nsc 57654
einecs 208-290-2
5,7,3'-trihydroxy-4'-methoxyflavanone
(s)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone
flavanone, 3',5,7-trihydroxy-4'-methoxy- (van)
KBIO2_005797
KBIO2_000661
KBIO2_003229
KBIOSS_000661
KBIO3_002028
KBIOGR_002311
SPECTRUM3_001104
PRESTWICK0_000124
SPECTRUM2_001793
NINDS_001039
SPBIO_001745
PRESTWICK1_000124
SPBIO_002107
SPECTRUM310012
PRESTWICK2_000124
SMP1_000148
bdbm23418
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-one
LMPK12140003
CHEMBL399121
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one
HMS503O19
H0721
HMS1568I10
HMS2095I10
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one
A828900
(s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one;hesperetin
HMS2230M09
CCG-38441
NCGC00016482-04
NCGC00016482-03
q9q3d557f1 ,
unii-q9q3d557f1
2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one
hesperetin [mi]
flavanone, 3',5,7-trihydroxy-4'-methoxy-
fema no. 4313
hesperetin [inci]
eriodictyol 4'-monomethyl ether
hesperetin [fhfi]
S2308
AKOS016339567
SCHEMBL39833
KS-5307
hesperitine
(s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one
HMS3649H22
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4h-1-benzopyran-4-one
6jp ,
DTXSID4022319
41001-90-5
HY-N0168
4'-methoxy-3',5,7-trihydroxyflavanone
AC-7970
flavanone, 3',5,7-trihydroxy-4'-methoxy- (van) (8ci)
5,7, 3'-trihydroxy-4'-methoxyflavanone
flavanone, 3',5, 7-trihydroxy-4'-methoxy- (van)
(2s)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4h-1-benzopyran-4-one (hesperetin)
(+-)-hesperetin
BBL104011
SW197026-2
STL557824
Q411310
sr-01000946723
SR-01000946723-1
hesperitin; hesperin; yso2; prestwick_908
BCP28273
BRD-K30553453-001-08-2
HMS3884N11
np-13
gtpl10953
4h-1-benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2s)-
H10029
discontinued. please see h289480 or h289501

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" On the basis of these experimental findings our present study postulate that co-administration of hesperetin with cisplatin chemotherapy may be promising preventive approach to limit the major mortal side effect of cisplatin."( The renoprotective activity of hesperetin in cisplatin induced nephrotoxicity in rats: Molecular and biochemical evidence.
Bodduluru, LN; Dahiya, V; Kasala, ER; Kumar, M; Lahkar, M, 2017
)
0.46
"Clinical utilization of doxorubicin (DOX), which is a commonly used chemotherapeutic, is restricted due to toxic effects on various tissues."( The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1).
Güzel, EE; Tektemur, A; Tektemur, NK, 2022
)
0.72

Pharmacokinetics

Hesperetin has antihyperuricemia activity. The elimination half-life for hesperetin was found to be 3. Naringenin and he Speretin were detected in plasma by RP-HPLC.

ExcerptReferenceRelevance
" Therefore, the objective of the present investigation was the evaluation of the pharmacokinetic parameters of hesperetin and naringenin in plasma and urine, after their single oral administration in humans in the form of solid dispersion capsules, and also to improve the absorption rate of flavanones by using aglycones rather than the naturally occurring glycosides."( Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects.
Bounartzi, MI; Georgarakis, M; Kanaze, FI; Niopas, I, 2007
)
0.34
" Pharmacokinetic parameters for hesperetin and naringenin, such as C(max), T(max), AUC(0-t), AUC(0-infinity), CL/F, V/F, t(1/2), MRT, A(e), A(e)((0-24)), and R(max) were calculated from their plasma or urine concentrations."( Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects.
Bounartzi, MI; Georgarakis, M; Kanaze, FI; Niopas, I, 2007
)
0.34
"The majority of pharmacokinetic studies of individual flavonoids or after ingestion of foodstuffs have overlooked the chirality of some of these xenobiotics."( Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices.
Andrews, PK; Davies, NM; Miranda, ND; Remsberg, CM; Vega-Villa, KR; Yáñez, JA, 2008
)
0.35
" To overcome this limitation, a phospholipid complex of hesperetin was prepared and evaluated for antioxidant activity and pharmacokinetic profile."( Exploring the effect of Hesperetin-HSPC complex--a novel drug delivery system on the in vitro release, therapeutic efficacy and pharmacokinetics.
Maiti, K; Mukherjee, K; Mukherjee, PK; Murugan, V; Saha, BP, 2009
)
0.35
" Naringenin and hesperetin were detected in plasma by RP-HPLC, pharmacokinetic parameters were processed using mode-independent methods with WINNONLIN."( Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula.
Cao, H; Chen, X; Lv, H; Sakurai, T; Sun, H; Sun, W; Wang, X; Zhou, J, 2010
)
0.36
"After oral administration of BZZW, both naringenin and hesperetin were detected in plasma, and demonstrated similar pharmacokinetic parameters."( Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula.
Cao, H; Chen, X; Lv, H; Sakurai, T; Sun, H; Sun, W; Wang, X; Zhou, J, 2010
)
0.36
"The distinct therapeutic orientations of the Chinese medical formula ZZWs with different Fructus Citrus Immaturus could be elucidated based on the pharmacokinetic parameters of constituents after oral administration."( Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula.
Cao, H; Chen, X; Lv, H; Sakurai, T; Sun, H; Sun, W; Wang, X; Zhou, J, 2010
)
0.36
" Taken together, these results showed that pharmacokinetic differences between non-antibiotic-exposed and pseudo-germ-free rats may be attributed to differing hesperidin uptake, as well as alterations in metabolic activities of intestinal flora."( Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats.
Han, SB; Jin, MJ; Kim, DH; Kim, IS; Kim, U; Kim, Y; Kwon, OS; Yoo, HH, 2010
)
0.36
" With pharmacokinetic analysis, the estimated pharmacokinetic parameters (i."( Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study.
Dong, T; Han, Y; Sakurai, T; Sun, H; Wang, X; Wu, X; Yan, G; Yang, J; Zhang, A, 2013
)
0.39
"0 software was applied to calculate the pharmacokinetic parameters while the SPSS 16."( [Effect of different compatibility of zhizi dahuang decoction on pharmacokinetics of naringenin and hesperetin].
Feng, F; Liu, XY, 2014
)
0.4
" This method has been successfully applied to the pharmacokinetic study following oral doses of 25, 50 and 100mg/kg and intravenous dose of 25mg/kg, and tissue distribution study following oral dose of 50mg/kg."( A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study.
Chen, R; Chen, Z; Huang, C; Huang, X; Li, J; Li, L; Ma, T; Meng, X; Qian, Z; Shen, C; Zang, H, 2016
)
0.43
"Hesperetin has antihyperuricemia activity, and the pharmacokinetic profiles of hesperetin may be altered by hyperuricemia."( Comparative Pharmacokinetic Study of Hesperetin after Oral Administration in Normal and Hyperuricemia Rats by UPLC-MS/MS.
Han, W; Han, Z; Li, K; Liu, X; Pan, Y; Wei, L; Xiong, H; Zhang, F; Zhao, D, 2021
)
0.62
"57% decreases in Cmax and CL/F, and resulted in 58."( Comparative Pharmacokinetic Study of Hesperetin after Oral Administration in Normal and Hyperuricemia Rats by UPLC-MS/MS.
Han, W; Han, Z; Li, K; Liu, X; Pan, Y; Wei, L; Xiong, H; Zhang, F; Zhao, D, 2021
)
0.62
"The pharmacokinetic parameters of hesperetin in hyperuricemia rats were reported for the first time."( Comparative Pharmacokinetic Study of Hesperetin after Oral Administration in Normal and Hyperuricemia Rats by UPLC-MS/MS.
Han, W; Han, Z; Li, K; Liu, X; Pan, Y; Wei, L; Xiong, H; Zhang, F; Zhao, D, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study, we established a melanogenesis regulation assay system using a fluorescent protein reporter combined with the promoters for the microphthalmia-associated transcription factor (MITF), tyrosinase (Tyr) and dopachrome tautomerase (Dct) genes in MeWo human melanoma cells."( Establishment of a melanogenesis regulation assay system using a fluorescent protein reporter combined with the promoters for the melanogenesis-related genes in human melanoma cells.
Chen, CY; Chiu, YW; Lin, CC; Lin, YJ; Yang, CH, 2015
)
0.42

Bioavailability

Hesperetin (HDND) possesses extensive bioactivities, however, its poor solubility and low bioavailability limit its application. The present study aimed to develop novel hesperetin-loaded on multiple wall carbon nanotubes (Hst-MWCNTs) to resolve the restricted bioavailability of he Speretin.

ExcerptReferenceRelevance
" Naringenin and hesperetin were bioavailable from the studied juices, but interindividual variation in bioavailability was remarkable."( Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice.
Alfthan, G; Aro, A; Erlund, I; Meririnne, E, 2001
)
0.31
" Moreover, data suggest that a high polyphenol intake may improve their bioavailability due to saturation of the intestinal secretion of conjugates."( The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites.
Besson, C; Manach, C; Mathevon, T; Morand, C; Remesy, C; Scalbert, A; Silberberg, M, 2006
)
0.33
" Therefore, the objective of the present investigation was the evaluation of the pharmacokinetic parameters of hesperetin and naringenin in plasma and urine, after their single oral administration in humans in the form of solid dispersion capsules, and also to improve the absorption rate of flavanones by using aglycones rather than the naturally occurring glycosides."( Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects.
Bounartzi, MI; Georgarakis, M; Kanaze, FI; Niopas, I, 2007
)
0.34
" The cumulative urinary recovery data indicated low bioavailability for both flavanone aglycones, owing to extensive first-pass metabolism partly by cleavage of the C-ring by the enzymes of intestinal bacteria leading to degradation products such as phenolic acids."( Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects.
Bounartzi, MI; Georgarakis, M; Kanaze, FI; Niopas, I, 2007
)
0.34
"Metabolism and transport from intestinal cells back into the lumen by ATP-binding cassette (ABC) transporters is believed to limit the bioavailability of flavonoids."( Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers.
Barron, D; Brand, W; Rein, MJ; Rietjens, IM; van Bladeren, PJ; van der Wel, PA; Williamson, G, 2008
)
0.35
" Although it shows appreciable bioavailability when administered orally, its faster elimination from body creates the need of frequent administration to maintain effective plasma concentration."( Exploring the effect of Hesperetin-HSPC complex--a novel drug delivery system on the in vitro release, therapeutic efficacy and pharmacokinetics.
Maiti, K; Mukherjee, K; Mukherjee, PK; Murugan, V; Saha, BP, 2009
)
0.35
" The present data show that bioavailability of naringenin is increased by conversion from rutinoside to glucoside, but the profile of the conjugates of flavanones formed and excreted in urine is neither affected by the absorption site nor by a 3-fold change in dose."( Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects.
Barron, D; Bouisset, F; Bredsdorff, L; Cornett, C; Nielsen, IL; Offord, E; Rasmussen, SE; Williamson, G, 2010
)
0.36
"Metabolism by phase II enzymes and transport from intestinal cells back into the lumen by ATP binding cassette (ABC) transporters limits the bioavailability of the flavanone hesperetin, the aglycone of hesperidin."( The effect of co-administered flavonoids on the metabolism of hesperetin and the disposition of its metabolites in Caco-2 cell monolayers.
Brand, W; Padilla, B; Rietjens, IM; van Bladeren, PJ; Williamson, G, 2010
)
0.36
"The bioavailability and urinary excretion of three dietary flavonoids, quercetin, hesperetin and naringenin, were investigated."( Relative bioavailability of the flavonoids quercetin, hesperetin and naringenin given simultaneously through diet.
Bredsdorff, L; Haraldsdóttir, J; Knuthsen, P; Krogholm, KS; Rasmussen, SE, 2010
)
0.36
" The effect of flavanone concentration and solubility of orange beverages on their bioavailability has been studied in a crossover study with 10 healthy volunteers."( Concentration and solubility of flavanones in orange beverages affect their bioavailability in humans.
Boza, J; Cerdá, B; Escudero, E; Espín, JC; García-Conesa, MT; Larrosa, M; Tomás-Barberán, FA; Vallejo, F; Zafrilla, MP, 2010
)
0.36
" However, absorption and metabolism of flavonoids are complex processes that determine its bioavailability which remain not clear until now."( Hesperidin and hesperetin membrane interaction: understanding the role of 7-O-glycoside moiety in flavonoids.
Creczynski-Pasa, T; Jaramillo, C; Lima, VR; Londoño-Londoño, J, 2010
)
0.36
" In this study, their interaction with specific ABC transporters, believed to play a role in the disposition and bioavailability of hesperetin, was studied using Sf9 membranes from cells overexpressing human BCRP (ABCG2), MRP2 (ABCC2) and MRP3 (ABCC3)."( Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells.
Barron, D; Brand, W; Dionisi, F; Krajcsi, P; Oosterhuis, B; Rietjens, IM; van Bladeren, PJ; Williamson, G, 2011
)
0.37
" We developed water-dispersible hesperetin by the process of micronization to enhance the bioavailability of hesperetin."( Bioavailability of orally administered water-dispersible hesperetin and its effect on peripheral vasodilatation in human subjects: implication of endothelial functions of plasma conjugated metabolites.
Harada, R; Kawai, Y; Kometani, T; Mukai, R; Murota, K; Nadamoto, T; Nakamura, H; Simizu, T; Takumi, H; Terao, J, 2012
)
0.38
"The objective of this study was to determine the ocular bioavailability of hesperidin and hesperetin, especially with respect to their distribution into the posterior segment of the eye, following systemic and topical administration in rabbits."( Evaluation of the intravenous and topical routes for ocular delivery of hesperidin and hesperetin.
Avula, B; Hippalgaonkar, K; Khan, IA; Majumdar, S; Srirangam, R, 2012
)
0.38
" However, hesperidin has a low bioavailability compared to hesperitin due to the rutinoside moiety attached to the flavonoid."( Hesperidinase encapsulation towards hesperitin production targeting improved bioavailability.
Furtado, AF; Nunes, MA; Ribeiro, MH, 2012
)
0.38
" Our results suggest that polyphenolic compounds might be potential structural bases and source to find and project nature-based, safe, orally bioavailable direct thrombin inhibitors."( Thrombin inhibitory activity of some polyphenolic compounds.
Bijak, M; Krotkiewski, H; Nowak, P; Pawlaczyk, I; Ponczek, M; Saluk, J; Wachowicz, B; Ziewiecki, R, 2014
)
0.4
"The effect of hesperidin encapsulation and particle size reduction on hesperetin bioavailability was assessed after the intake of orange flavanone beverages."( Encapsulation and micronization effectively improve orange beverage flavanone bioavailability in humans.
Borrego, F; Tomás-Barberán, FA; Tomás-Navarro, M; Vallejo, F, 2014
)
0.4
"The study provides novel information on the potential involvement of the colonic microbiota in the overall bioavailability of orange juice (poly)phenols through the production of phenylpropionic acids and subsequent hepatic conversions that lead to hippuric acid and its hydroxylated analogues."( In vitro colonic catabolism of orange juice (poly)phenols.
Borges, G; Calani, L; Clifford, MN; Crozier, A; Del Rio, D; Ky, I; Pereira-Caro, G; Ribas, A; Roberts, SA, 2015
)
0.42
"In the present study, nanocrystalline solid dispersion (NSD) was developed to enhance the release rate and oral bioavailability of hesperetin (HRN)."( Oral bioavailability and pharmacodynamic activity of hesperetin nanocrystals generated using a novel bottom-up technology.
Bansal, AK; Jain, S; Pawar, YB; Shete, G; Thanki, K, 2015
)
0.42
" However, hesperetin's poor solubility and low bioavailability limit its wide application."( Intestinal absorption mechanisms of MTBH, a novel hesperetin derivative, in Caco-2 cells, and potential involvement of monocarboxylate transporter 1 and multidrug resistance protein 2.
Chen, R; Chen, Z; Hu, C; Hu, T; Huang, C; Li, J; Li, Y; Meng, X; Qian, Z; Shen, C, 2015
)
0.42
"46 % of the amount of glucuronides/sulfates, the absolute bioavailability of MTBH was approximately 31."( Single Dose Oral and Intravenous Pharmacokinetics and Tissue Distribution of a Novel Hesperetin Derivative MTBH in Rats.
Chen, R; Chen, Z; Hu, C; Hu, T; Huang, C; Li, J; Li, Y; Meng, X; Qian, Z; Shen, C, 2016
)
0.43
"Cytochrome P-450 (CYP) enzymes and P-glycoprotein (P-gp) play an important role in the oral bioavailability and first-pass-metabolism (FPM) of many drugs."( Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats.
Kilaru, N; Mullapudi, SS; Nuthakki, S; Pendyala, S; Pingili, R; Vemulapalli, S, 2016
)
0.43
" Hesperetin (HDND) possesses extensive bioactivities, however, its poor solubility and low bioavailability limit its application."( Intestinal transport of HDND-7, a novel hesperetin derivative, in in vitro MDCK cell and in situ single-pass intestinal perfusion models.
Chen, R; Huang, C; Li, J; Li, L; Li, Y; Ma, T; Meng, X; Qian, Z; Shen, C, 2017
)
0.46
"4 aqueous buffer was coupled with the in vitro (1,1-diphenyl-2-picryl hydroxyl free radical antioxidant assay and RBC antihemolytic assay) studies to present a complete preliminary data on the improved bioavailability of hesperetin eutectics."( Is Failure of Cocrystallization Actually a Failure? Eutectic Formation in Cocrystal Screening of Hesperetin.
Bhalla, Y; Chadha, K; Chadha, R; Karan, M; Vasisht, K, 2017
)
0.46
"Drug nanosuspension is one of the established methods to improve the bioavailability of poorly soluble drugs."( Production of drug nanosuspensions: effect of drug physical properties on nanosizing efficiency.
Liu, T; Möschwitzer, JP; Müller, RH, 2018
)
0.48
" Nevertheless, their predictive value for bioavailability can be questioned."( A Critical Evaluation of In Vitro Hesperidin 2S Bioavailability in a Model Combining Luminal (Microbial) Digestion and Caco-2 Cell Absorption in Comparison to a Randomized Controlled Human Trial.
Grootaert, C; Jacobs, G; Noten, B; Pitart, J; Possemiers, S; Salden, B; Smagghe, G; Van Camp, J; Van Rymenant, E; Voorspoels, S, 2018
)
0.48
" Nanocrystals can be used to improve the bioavailability of poorly soluble actives not only for oral, but also for topical application."( Nanocrystals for improved dermal drug delivery.
Dietrich, H; Geisel, N; Gerst, M; Huang, J; Keck, CM; Pelikh, O; Scholz, P; Stahr, PL, 2018
)
0.48
" The present study aimed to develop nanocrystalline solid dispersions (NSD) of HRN and evaluating the oral bioavailability in rats."( Nanocrystalline solid dispersions (NSD) of hesperetin (HRN) for prevention of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in Sprague-Dawley (SD) rats.
Bansal, AK; Navik, U; Sheokand, S, 2019
)
0.51
"Dietary constituents can influence the bioavailability of carotenoids."( Hesperetin and Hesperidin Improved β-Carotene Incorporation Efficiency, Intestinal Cell Uptake, and Retinoid Concentrations in Tissues.
Huang, W; Jiang, N; Li, D; Liu, C; Nie, M; Zhang, Z, 2019
)
0.51
" DG-Hes significantly improved the in vitro passive permeation, ex vivo corneal permeation, and in vivo ocular bioavailability of Hes."( Preparation and in vitro/in vivo evaluations of novel ocular micelle formulations of hesperetin with glycyrrhizin as a nanocarrier.
Chen, H; Lan, J; Song, K; Wu, X; Zhang, F, 2021
)
0.62
"Poor aqueous solubility of drug substances is associated with poor bioavailability and thus hampers the effective use of many potent active pharmaceutical ingredients."( Investigating hesperetin nanocrystals with tailor-made sizes for the prevention and treatment of Alzheimer's disease.
Eckert, GP; Grewal, R; Keck, CM; Stahr, PL, 2021
)
0.62
"This study aimed to prepare a nanoemulsion vehicle to improve the oral bioavailability of hesperetin."( Nanoemulsion for Improving the Oral Bioavailability of Hesperetin: Formulation Optimization and Absorption Mechanism.
Huang, Y; Liu, R; Tian, Y; Wang, D; Wang, M; Xia, Z; Zeng, F, 2021
)
0.62
"The present study aimed to develop novel hesperetin-loaded on multiple wall carbon nanotubes (Hst-MWCNTs) to resolve the restricted bioavailability of hesperetin (Hst) and to enhance its preventive effect on cerebral ischemia-reperfusion (I/R)."( Evaluation of hesperetin-loaded on multiple wall carbon nanotubes on cerebral ischemia/reperfusion injury in rats.
Hajizadeh Moghaddam, A; Hasantabar, V; Mokhtari Sangdehi, SR; Shirej Pour, Y, 2021
)
0.62
" In this study, we successfully prepared a novel, self-assembled micelle based on Rebaudioside A (RA) for oral delivery of HSP with improved bioavailability and therapeutic effects."( Improved bioavailability and anticancer efficacy of Hesperetin on breast cancer via a self-assembled rebaudioside A nanomicelles system.
Chen, Z; Di, G; Fan, J; Guo, C; Li, Q; Qi, X; Wang, J; Wu, X, 2021
)
0.62
" To conclude the use of HP-β-CD as a carrier in the formation of an amorphous inclusion complex seems to be a promising approach to improve the biological activity and bioavailability of Hed and Het."( Amorphous Inclusion Complexes: Molecular Interactions of Hesperidin and Hesperetin with HP-Β-CD and Their Biological Effects.
Cielecka-Piontek, J; Płazińska, A; Płaziński, W; Rosiak, N; Tykarska, E; Wdowiak, K; Żarowski, M, 2022
)
0.72
" A hesperetin derivative (HD) was synthesized in our laboratory to increase the bioavailability and the water solubility of hesperetin."( Hesperetin derivative decreases CCl
Chen, SY; Chen, X; Cheng, M; Huang, C; Li, J; Li, XF; Wang, A; Wu, S; Wu, YY; Xu, JJ; Zhu, S, 2022
)
0.72
" However, the bioavailability of these compounds is limited due to low solubility and restricts their use as pro-healthy agents."( Bioavailability of Hesperidin and Its Aglycone Hesperetin-Compounds Found in Citrus Fruits as a Parameter Conditioning the Pro-Health Potential (Neuroprotective and Antidiabetic Activity)-Mini-Review.
Bazan-Woźniak, A; Cielecka-Piontek, J; Pietrzak, R; Walkowiak, J; Wdowiak, K, 2022
)
0.72
" Despite their various benefits, they have poor solubility, which reduces their bioavailability and absorption."( Nanophytosomes of hesperidin and of hesperetin: Preparation, characterization, and in vivo evaluation.
Amirinejad, M; Badiee, A; Davoodi, J; Gheybi, F; Omidfar, F, 2023
)
0.91
" Piperine has the ability to improve the bioavailability of many compounds when co-administered."( Amorphous System of Hesperetin and Piperine-Improvement of Apparent Solubility, Permeability, and Biological Activities.
Cielecka-Piontek, J; Miklaszewski, A; Pietrzak, R; Wdowiak, K, 2023
)
0.91
"The purpose of the study is to assess the bioavailability and neuroprotective effect of hesperetin (Hesp)-loaded nanofibers."( Hesperetin-loaded polymeric nanofibers: assessment of bioavailability and neuroprotective effect.
Pattnaik, S; Yadav, YC, 2023
)
0.91
" Because of the greatly improved bioavailability of Hesp, the Hesp-loaded nanofibers significantly protected rats from scopolamine-induced amnesia."( Hesperetin-loaded polymeric nanofibers: assessment of bioavailability and neuroprotective effect.
Pattnaik, S; Yadav, YC, 2023
)
0.91

Dosage Studied

Hsperetin, a flavanone present as a disaccharide in oranges, increased LDLR mRNA levels 3. Pharmacokinetic analysis showed that both he Speretin and naringenin were rapidly absorbed and their concentrations in plasma observed 20 min after dosing.

ExcerptRelevanceReference
" When a solution containing Hsp is dosed with NaOCl at pH 7, chlorine substitution into Hsp occurs exclusively into the meta-dihydroxy substituted ring."( Reactions of the flavonoid hesperetin with chlorine: a spectroscopic study of the reaction pathways.
Benjamin, MM; Gallard, H; Korshin, GV; Lu, J, 2004
)
0.32
" Permeation issues for topical delivery systems of such effects are occasionally problematic, and in view of the fact that microemulsions are potential carriers for transdermal delivery system, the objective of this study was to design an optimal microemulsion formulation by in vitro permeation study for hesperetin topical dosage form and determine its topical photoprotective effect and skin irritation by in vivo study."( In vitro permeation and in vivo whitening effect of topical hesperetin microemulsion delivery system.
Huang, CT; Huang, YB; Lee, KF; Tsai, YH; Wu, PC, 2010
)
0.36
" Doxorubicin was administered at the dosage of 4 mg/kg bw/week, ip for a period of 5 consecutive weeks."( Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat.
Jena, GB; Kushwaha, S; Tripathi, DN; Trivedi, PP, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Active Lifestyle & Fitness1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Animal Advanced Test Pill Pack -- 21 PacksAnimalActive Lifestyle & FitnessArachidonic Acid, Hesperetin2024-11-29 10:47:42

Roles (3)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
flavonoidsAny organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them.
monomethoxyflavanoneAny methoxyflavanone that is flavanone substituted by a methoxy group.
trihydroxyflavanoneA hydroxyflavanone carrying three hydroxy substituents.
3'-hydroxyflavanonesAny hydroxyflavanone with a hydroxy substituent at position 3' of the phenyl ring.
4'-methoxyflavanonesAny methoxyflavanone having a methoxy substituent located at position 4'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (63)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID485281
TDP1 proteinHomo sapiens (human)Potency23.42840.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency10.00000.180013.557439.8107AID1460
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID902
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency22.38720.001815.663839.8107AID894
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency89.12510.425612.059128.1838AID504891
survival motor neuron protein isoform dHomo sapiens (human)Potency31.62280.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.62340.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency14.21910.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency14.21910.025120.237639.8107AID886
LuciferasePhotinus pyralis (common eastern firefly)Potency15.10140.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency20.15060.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency30.05340.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.01190.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.51190.001318.074339.8107AID926; AID938
serine-protein kinase ATM isoform aHomo sapiens (human)Potency39.81070.707925.111941.2351AID485349
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency24.90530.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency5.62340.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency25.11890.316212.443531.6228AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.47760.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.92440.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency79.43283.548119.542744.6684AID743266
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.98110.039816.784239.8107AID1454
ras-related protein Rab-9AHomo sapiens (human)Potency6.30960.00022.621531.4954AID485297
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency6.30960.00798.23321,122.0200AID2546
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.92440.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Integrin beta-3Homo sapiens (human)Potency25.11890.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency25.11890.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.92440.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.92441.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki0.45410.00021.10439.9000AID1254159
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)78.76000.00312.16029.6000AID1515260
Carbonic anhydrase 1Homo sapiens (human)Ki10.00000.00001.372610.0000AID1254155
Carbonic anhydrase 2Homo sapiens (human)Ki10.00000.00000.72369.9200AID1254156
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)2.78600.00791.24789.9000AID502474
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)34.64700.00011.774010.0000AID502473
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)34.15000.00402.92669.9600AID753300; AID753308
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)2,476.10010.00000.933210.0000AID654699
Carbonic anhydrase 4Homo sapiens (human)Ki0.10210.00021.97209.9200AID1254157
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)0.28000.00010.444410.0000AID1395903
Carbonic anhydrase 7Homo sapiens (human)Ki0.00330.00021.37379.9000AID1254158
Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)54.60000.00201.703510.0000AID1799639
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)54.60000.00010.72667.8000AID1799639
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)0.51100.00130.86969.9000AID502475
Carboxylic ester hydrolase Equus caballus (horse)IC50 (µMol)1,774.10000.00512.69848.5000AID654701
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Ke10.00000.00000.24883.0700AID311281
Delta-type opioid receptorHomo sapiens (human)Ke10.00000.00010.69799.0700AID311282
Kappa-type opioid receptorHomo sapiens (human)Ke10.00000.00000.35405.8100AID311280
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (353)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (108)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (83)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (200)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1645834Screen against P. berghei liver stage (PbLuc), transformed with Luciferase, at 10uM2020ACS infectious diseases, 04-10, Volume: 6, Issue:4
Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials.
AID1645837Screen against P. falciparum Stg V gametocytes, at 2uM2020ACS infectious diseases, 04-10, Volume: 6, Issue:4
Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials.
AID1645833Screen against P. berghei liver stage (PbLuc), transformed with Luciferase, at 2uM2020ACS infectious diseases, 04-10, Volume: 6, Issue:4
Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials.
AID1645836Screen against P. falciparum Asexual Blood Stage (ABS), at 5uM2020ACS infectious diseases, 04-10, Volume: 6, Issue:4
Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials.
AID1533712Inhibition of human liver microsomes CYP1B1 using Ethoxyresorufin as substrate after 2 mins in presence of NADPH by EROD assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1.
AID1645835Toxicity liver stage against HepG2, at 10uM2020ACS infectious diseases, 04-10, Volume: 6, Issue:4
Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials.
AID714355Inhibition of alpha glucosidase at 1 mM using pNPG substrate incubated for 60 mins2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis and anti-hyperglycemic activity of hesperidin derivatives.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID402478Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality at 250 uM after 15 mins by [methyl-3H]thymidine incorporation assay1997Journal of natural products, Aug, Volume: 60, Issue:8
Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID1264955Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID406997Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID293299Antioxidant activity in BALB/c mouse BM cells assessed as inhibition of ROS production2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID753299Binding affinity to SARS coronavirus 3C-like protease by SPR analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.
AID404069In vivo antitumor activity against mouse L1210 cells
AID1264950Cytotoxicity against human MSC assessed as cell viability at 1 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID109825Body weight of the high cholesterol-fed mice after 0 day2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Hypocholesterolemic activity of hesperetin derivatives.
AID1264951Cytotoxicity against human MSC assessed as cell viability at 5 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1129937Retention time of the compound by PDA chromatography2014Journal of natural products, Apr-25, Volume: 77, Issue:4
UPLC-MS-ELSD-PDA as a powerful dereplication tool to facilitate compound identification from small-molecule natural product libraries.
AID1265118Inhibition of recombinant human N-terminal His6-tagged AKR1B10 expressed in Escherichia coli BL21 cells using all-trans-retinal as substrate at 20 uM incubated for 15 mins by HPLC method2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
AID1278584Antiinflammatory activity in mouse RAW264.7 assessed as decrease in LPS-induced TNF-alpha production at 10 uM pretreated with 1 ug/ml LPS for 22 hrs followed by addition of compound for 24 hrs by ELISA2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Hesperetin derivatives: Synthesis and anti-inflammatory activity.
AID311283Selectivity for antagonist activity at human mu opioid receptor to kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID386552Ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco-2 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID502475Inhibition of human CYP1B1 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID1717774Inhibition of SARS-CoV 3C-like protease expressed in African green monkey Vero cells by dual luciferase reporter assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID456318DPPH radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID477850Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID1254157Inhibition of human recombinant carbonic anhydrase 4 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID587206Inhibition of mushroom tyrosinase at 100 uM preincubated for 10 mins before addition of 1.7 mM L-tyrosine measured after 20 mins by spectrophotometric method2011Journal of natural products, Feb-25, Volume: 74, Issue:2
Prenylated flavanones with anti-tyrosinase activity from Dalea boliviana.
AID663325Increase in LXRalpha-mediated ABCA1 mRNA expression in human THP1 cells at 5 to 15 uM after 24 hrs by RT-PCR analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID386542Stability in hank's balanced salt solution at 15 uM after 60 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID717770Inhibition of TGF-beta1 induced TGF-beta type 2 receptor dimerization in human HeLa cells assessed as receptor dimers by bleaching-step counting assay (Rvb = 39.9 +/- 2.5%)2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID404692Inhibition of human salivary alpha-amylase2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.
AID749998Binding affinity to recombinant paraoxonase-1 (unknown origin) expressed in Escherichia coli2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
The effects and mechanism of flavonoid-rePON1 interactions. Structure-activity relationship study.
AID456316ABTS radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID311280Antagonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID311284Selectivity for antagonist activity at human delta opioid receptor to kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID749999Binding affinity to recombinant paraoxonase-1 (unknown origin) expressed in Escherichia coli after 5 mins by Trp-fluorescence quenching method2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
The effects and mechanism of flavonoid-rePON1 interactions. Structure-activity relationship study.
AID1330156Cytotoxicity against human HCT116 cells assessed as decrease in cell viability at 80 uM after 24 hrs by CCK-8 assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID386544Stability in hank's balanced salt solution at 15 uM after 180 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1254155Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID339057Inhibition of Moloney murine leukemia virus reverse transcriptase using (ribocytidylic acid)n(deoxyguanylic acid)12-18 as template primer by liquid scintillation counting1992Journal of natural products, Feb, Volume: 55, Issue:2
Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity.
AID663326Increase in LXRalpha-mediated ABCA1 protein expression in human THP1 cells at 5 to 15 uM after 48 hrs by Western blotting analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID654699Inhibition of human erythrocyte AChE assessed as acetylthiocholine iodide hydrolysis after 10 mins preincubation by spectrophotometry2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Cholinestrase inhibitory effects of geranylated flavonoids from Paulownia tomentosa fruits.
AID1264953Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID386545Stability in hank's balanced salt solution at 15 uM after 24 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID690148Reducing activity assessed as chlorogenic acid equivalent per mmol standard at 37 degC for 30 mins by Folin-Ciocalteu reagent assay assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID477846Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID1730825Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL1beta production at 10 uM preincubated for 1 hr followed by LPS stimulation and measured after 22 hrs by ELISA2021European journal of medicinal chemistry, Mar-05, Volume: 213Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
AID1395903Inhibition of DPP4 (unknown origin) using Gly-Pro-AMC as substrate preincubated for 4 secs followed by substrate addition and measured after 30 mins by luminescence assay2018European journal of medicinal chemistry, May-10, Volume: 151Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
AID663327Induction of PPARgamma enhancer activity in human THP1 cells after 24 hrs by luciferase reporter gene analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID1264952Cytotoxicity against human MSC assessed as cell viability at 10 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID406995Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID339056Inhibition of Moloney murine leukemia virus reverse transcriptase using (riboadenylic acid)n(deoxythymidylic acid)12-18 as template primer by liquid scintillation counting1992Journal of natural products, Feb, Volume: 55, Issue:2
Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity.
AID663328Induction of PPARgamma-mediated ABCA1 promoter activity in human THP1 cells after 24 hrs by luciferase reporter gene analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID654700Mixed type inhibition of human erythrocyte AChE using acetylthiocholine iodide as substrate by Lineweaver-Burk double-reciprocal-plot and dixon plot analysis2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Cholinestrase inhibitory effects of geranylated flavonoids from Paulownia tomentosa fruits.
AID717767Antimigratory activity against human HeLa cells assessed as inhibition of TGF-beta1-induced cell migration at 100 uM after 24 hrs by scratch motility assay2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID386551Apparent permeability across PAMPA membrane assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID717771Inhibition of TGF-beta type 2 receptor dimerization in human HeLa cells at 100 uM after 1 hr by single-molecule fluorescence microscopy2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID1129936Retention time of the compound by ELSD chromatography2014Journal of natural products, Apr-25, Volume: 77, Issue:4
UPLC-MS-ELSD-PDA as a powerful dereplication tool to facilitate compound identification from small-molecule natural product libraries.
AID717768Antimigratory activity against human HeLa cells assessed as inhibition of TGF-beta1-induced cell invasion across collagen matrix at 100 uM after 1 hr by collagen-based cell Invasion assay2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID502474Inhibition of human CYP1A1 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID1730820Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess method relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 213Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
AID1603995Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181The Mediterranean Diet as source of bioactive compounds with multi-targeting anti-cancer profile.
AID717765Antagonist activity at human TGF-beta receptor in HeLa cells assessed as suppression of nuclear translocation of Smad3 at 100 uM after 1 hr by immunofluorescence imaging2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID1254159Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID1264947Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 10 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID439368Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 25 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1330164Increase in JNK1 phosphorylation at Thr183/Tyr185 residues in human HCT116 cells at 50 to 200 uM after 12 hrs by Western blot analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID717769Cytotoxicity against human HeLa cells at 1 to 200 uM after 24 hrs by MTS proliferation assay2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID690144Antioxidant activity in human HepG2 cells assessed as reduction of oleic acid-induced ROS generation incubated for 24 hrs by DHCF-DA based fluorimetric assay relative to untreated control2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID753300Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.
AID717763Inhibition of TGF-beta1 induced TGF-beta type 2 receptor dimerization in human HeLa cells at 100 uM after 1 hr by single-molecule fluorescence microscopy2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID1264961Cytotoxicity against human MSC assessed as increase in cell number at 1 to 10 uM after 9 days by methylene blue staining based microscopy relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1254158Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID690145Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID1744553Permeability constant, logPe of compound incubated for 2 to 30 hrs by PAMPA assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID439372Agonist activity at human PPARalpha expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 40 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID386549Apparent permeability from basolateral to apical side in human Caco-2 cells assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID717762Displacement of biotinylated TGF-beta1 from human TGF-beta type 2 receptor at 100 uM after 1 hr by avidin-FITC-based flow cytometry2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID400608Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID1264956Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID406994Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol at 20 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID1744549Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state at 10 uM incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID1330159Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 50 uM after 24 hrs by FITC-annexin V/propidium iodide staining based fluorescence assay (Rvb = 3%)2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID477851Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID663324Induction of LXRalpha-mediated ABCA1 promoter activity in human THP1 cells after 24 hrs by luciferase reporter gene analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID681200TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 uM, Hesperetin: 50 uM) in BCRP-expressing MCF-7 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID353303Increase in EGR1 mRNA expression in human HEK293 cells at 20 ug/mL after 6 to 12 hrs by dual-glo luciferase assay relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Relationships between the structures of flavanone derivatives and their effects in enhancing early growth response-1 gene expression.
AID654839Mixed type inhibition of equine BChE using butyrylthiocholine iodide as substrate by Lineweaver-Burk double-reciprocal-plot and dixon plot analysis2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Cholinestrase inhibitory effects of geranylated flavonoids from Paulownia tomentosa fruits.
AID406996Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol at 40 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID477848Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID753308Inhibition of recombinant SARS coronavirus 3C-like protease trans-cleavage activity by ELISA2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.
AID1730821Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess method2021European journal of medicinal chemistry, Mar-05, Volume: 213Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
AID1744550Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID386543Stability in hank's balanced salt solution at 15 uM after 120 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID663323Induction of LXRalpha enhancer activity in human THP1 cells after 24 hrs by luciferase reporter gene analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID1730824Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 10 uM preincubated for 1 hr followed by LPS stimulation and measured after 22 hrs by ELISA2021European journal of medicinal chemistry, Mar-05, Volume: 213Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
AID1330165Increase in JNK2 phosphorylation at Thr183/Tyr185 residues in human HCT116 cells at 50 to 200 uM after 12 hrs by Western blot analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID386548Apparent permeability from basolateral to apical side in human Caco-2 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID736341Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 50 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID1070435Activation of Nrf2 (unknown origin) expressed in CHO-ARE luc cells at 10 to 30 uM after 18 hrs by luciferase reporter gene assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Identification of chromomoric acid C-I as an Nrf2 activator in Chromolaena odorata.
AID663329Induction of ApoA1-mediated cholesterol efflux in human THP1 cells after 12 hrs by fluorometric analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID386541Stability in hank's balanced salt solution at 15 uM after 20 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1744547Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL complex formation at 10 uM incubated for 15 mins in presence of cardiolipin by Trp-59 fluorescence assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID681156TP_TRANSPORTER: drug resistance (SN-38) in BCRP-expressing K562 cells2004Cancer research, Jun-15, Volume: 64, Issue:12
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
AID682237TP_TRANSPORTER: inhibition of Fexofenadine uptake (Fexofenadine: 1? uM, Hesperitin: 5 uM) in Oatp3-expressing HeLa cells2002Clinical pharmacology and therapeutics, Jan, Volume: 71, Issue:1
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
AID1730826Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL6 production at 10 uM preincubated for 1 hr followed by LPS stimulation and measured after 22 hrs by ELISA2021European journal of medicinal chemistry, Mar-05, Volume: 213Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
AID477845Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID386547Apparent permeability from apical to basolateral side in human Caco-2 cells assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1330158Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 50 uM after 24 hrs by FITC-annexin V/propidium iodide staining based fluorescence assay (Rvb = 6%)2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID1264957Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1330155Anticlonogenic activity in human HCT116 cells after 6 days by crystal violet staining based assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID1278583Antiinflammatory activity in mouse RAW264.7 assessed as decrease in LPS-induced IL-6 production at 10 uM pretreated with 1 ug/ml LPS for 22 hrs followed by addition of compound for 24 hrs by ELISA2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Hesperetin derivatives: Synthesis and anti-inflammatory activity.
AID1264954Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID293298Antioxidant activity assessed as inhibition of superoxide production by xanthine/xanthine oxidase method2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID293297Antioxidant activity assessed as DPPH radical scavenging activity after 20 min2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID1278580Octanol/water partition coefficient, logP of the compound by shake flask method2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Hesperetin derivatives: Synthesis and anti-inflammatory activity.
AID311281Antagonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID404070In vivo antitumor activity against mouse CA-755 cells
AID515157Antimutagenic activity in Salmonella Typhimurium TA98 assessed as inhibition of 3-nitrofluoranthene-induced mutation by Ames test2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Multivariate QSAR study on the antimutagenic activity of flavonoids against 3-NFA on Salmonella typhimurium TA98.
AID1264945Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 1 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID477847Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID1775658Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay2021Journal of natural products, 03-26, Volume: 84, Issue:3
Sesquiterpenoids from
AID717764Antagonist activity at human TGF-beta receptor in HeLa cells assessed as reduction in TGF-beta1-induced Smad3 phosphorylation at 100 uM after 1 hr by Western blot analysis2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID690143Inhibition of oleic acid-induced triglyceride over-accumulation in human HepG2 cells incubated for 24 hrs relative to untreated control2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID663330Cytotoxicity against human THP1 cells up to 100 uM after 24 hrs by WST8 assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.
AID120250Effect on plasma total cholesterol in high cholesterol-fed mice after 0 day2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Hypocholesterolemic activity of hesperetin derivatives.
AID456319ABTS radical scavenging activity assessed as vitamin C equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID681186TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 uM, Hesperetin: 50 uM) in BCRP-expressing NCI-H460 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID477849Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID379054Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1730822Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 40 uM measured after 24 hrs by MTT assay relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 213Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
AID439367Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 5 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID717761Inhibition of TGF-beta1 ligand binding to TGF-beta type 2 receptor in human HeLa cells at 100 uM after 1 hr by atomic force microscopy (Rvb = 23.4 +/- 2.5%)2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID1364658Inhibition of human 17beta-HSD2 expressed in HEK293 cell lysates assessed as residual enzyme activity at 40 uM incubated for 10 mins using [2,4,6,7-3H]-estradiol and NAD+ by scintillation counting method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.
AID1264946Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 5 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID439371Agonist activity at human PPARalpha expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 25 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID386550Apparent permeability across PAMPA membrane2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID386546Apparent permeability from apical to basolateral side in human Caco-2 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID456317Antioxidant activity assessed as trolox equivalent by TEAC assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1264958Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1631834Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms after 72 hrs by resazurin-based assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID404067In vivo antitumor activity against mouse S180 cells
AID502473Inhibition of human CYP1A2 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID311282Antagonist activity at human delta opioid receptor expressed in CHO cells by [35S]GTPgammaS assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID1775659Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2021Journal of natural products, 03-26, Volume: 84, Issue:3
Sesquiterpenoids from
AID717766Antagonist activity at human TGF-beta receptor in HeLa cells assessed as reduction in TGF-beta1-induced p21 expression at 100 uM after 24 hrs by Western blot analysis2012European journal of medicinal chemistry, Dec, Volume: 58Hesperetin: an inhibitor of the transforming growth factor-β (TGF-β) signaling pathway.
AID1330157Induction of apoptosis in human HCT116 cells assessed as viable cells at 50 uM after 24 hrs by FITC-annexin V/propidium iodide staining based fluorescence assay (Rvb = 90%)2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID1254156Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID1278582Cytotoxicity against mouse RAW264.7 cells at 1 to 10 uM for 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Hesperetin derivatives: Synthesis and anti-inflammatory activity.
AID736345Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 25 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID654701Inhibition of equine BChE assessed as butyrylthiocholine iodide hydrolysis after 10 mins preincubation by spectrophotometry2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Cholinestrase inhibitory effects of geranylated flavonoids from Paulownia tomentosa fruits.
AID109826Body weight of the high cholesterol-fed mice after 10 day2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Hypocholesterolemic activity of hesperetin derivatives.
AID1603992Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181The Mediterranean Diet as source of bioactive compounds with multi-targeting anti-cancer profile.
AID402477Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality at 250 uM preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining1997Journal of natural products, Aug, Volume: 60, Issue:8
Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID768928Inhibition of human thrombin amidolytic activity using D-Phe-Pip-Arg-pNA as substrate at 0.1 to 1000 uM preincubated for 10 mins followed by substrate addition measured every 12 secs for 10 mins by spectrophotometric analysis2014Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 23Thrombin inhibitory activity of some polyphenolic compounds.
AID1744548Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL peroxidase activity at 10 uM up to 20 mins in presence of cardiolipin by Amplex red staining based fluorescence assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID120251Effect on plasma total cholesterol in high cholesterol-fed mice after 10 day2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Hypocholesterolemic activity of hesperetin derivatives.
AID1515260Inhibition of LSD1 (unknown origin) by fluorescence assay2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
AID1744554Octanol-water distribution coefficient, log D of the compound at pH 7.4 after 1 hr by UV-VIS spectroscopic analysis2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID690149Reducing activity by cyclic voltammetry2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID1330160Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 50 uM after 24 hrs by FITC-annexin V/propidium iodide staining based fluorescence assay (Rvb = 2%)2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and biological evaluation of hesperetin derivatives as agents inducing apoptosis.
AID1424434Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Dec-15, Volume: 142Recent discoveries of anticancer flavonoids.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1799639Kinase Assay from Article 10.1002/cbic.201000487: \\Biological evaluation and structural determinants of p38u00CEu00B1 mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.\\2010Chembiochem : a European journal of chemical biology, Dec-10, Volume: 11, Issue:18
Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (579)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (0.86)18.7374
1990's18 (3.11)18.2507
2000's95 (16.41)29.6817
2010's315 (54.40)24.3611
2020's146 (25.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.09 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index77.22 (26.88)
Search Engine Supply Index2.97 (0.95)

This Compound (39.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials15 (2.56%)5.53%
Reviews1 (10.00%)6.00%
Reviews28 (4.79%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
Other542 (92.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]